UVA Joins Trial to Test COVID-19 Patients With Antiviral Drug

CHARLOTTESVILLE, Va. (WSET) --UVA Health announced Thursday that they will join a national clinical trial testing a potential COVID-19 medication.

Hospitalized adult patients with COVID-19 and significant symptoms – including difficulty breathing, using supplemental oxygen or needing a ventilator – can now choose to participate in the trial.

UVA Health said the trial will evaluate the safety and effectiveness of remdesivir, an antiviral drug that has been tested in humans with Ebola virus. They said it has shown promise in animal studies against Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), which are caused by different types of coronavirus.

“Finding an effective treatment will be incredibly important in our battle against COVID-19,” said K. Craig Kent, MD, UVA’s executive vice president for health affairs. “I am pleased that UVA is a part of this valuable study.”

For more on this story, visit our media partner, ABC 13 -WSET.

More information also at UVA Health.


Sponsored Content

Sponsored Content